Structure-based  	Structure-based  	 JJ	O
design  	design  	 NN	O
of  	of  	 IN	O
phthalimide  	phthalimide  	 JJ	B-NP
derivatives  	derivatives  	 NNS	I-NP
as  	as  	 IN	O
potential  	potential  	 JJ	B-NP
cyclooxygenase-2  	cyclooxygenase-2  	 NNP	I-NP
( 	( 	 -LRB-	O
COX-2 	COX-2 	 NNP	B-NP
)  	)  	 -RRB-	O
inhibitors 	inhibitors 	 NN	O
:  	:  	 :	O
anti-inflammatory  	anti-inflammatory  	 JJ	B-NP
and  	and  	 CC	O
analgesic  	analgesic  	 JJ	O
activities  	activities  	 NNS	O
A  	A  	 DT	O
group  	group  	 NN	O
of  	of  	 IN	O
30  	30  	 CD	O
cyclic  	cyclic  	 CD	B-NP
imides  	imides  	 NNS	I-NP
( 	( 	 -LRB-	O
1-10a-c 	1-10a-c 	 NNP	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
designed  	designed  	 VBN	O
for  	for  	 IN	O
evaluation  	evaluation  	 NN	O
as  	as  	 IN	O
a  	a  	 DT	O
selective  	selective  	 JJ	B-NP
COX-2  	COX-2  	 CD	I-NP
inhibitor  	inhibitor  	 NNS	I-NP
and  	and  	 CC	O
investigated  	investigated  	 VBD	O
in vivo  	in vivo  	 CD	O
for  	for  	 IN	O
anti-inflammatory  	anti-inflammatory  	 JJ	B-NP
and  	and  	 CC	O
analgesic  	analgesic  	 JJ	O
activities 	activities 	 NNS	O
.  	.  	 .	O
Compounds  	Compounds  	 NNP	O
6a 	6a 	 NNP	O
,  	,  	 ,	O
6b 	6b 	 NNP	O
,  	,  	 ,	O
7a  	7a  	 NNP	O
and  	and  	 CC	O
7b  	7b  	 FW	O
exhibit  	exhibit  	 FW	O
optimal  	optimal  	 FW	B-NP
COX-2  	COX-2  	 FW	I-NP
inhibitory  	inhibitory  	 FW	I-NP
potency  	potency  	 FW	I-NP
( 	( 	 -LRB-	O
IC50 = 0.18 	IC50 = 0.18 	 NNP	B-NP
,  	,  	 ,	O
0.24 	0.24 	 CD	O
,  	,  	 ,	O
0.28  	0.28  	 CD	O
and  	and  	 CC	O
0.36 μM 	0.36 μM 	 NNP	O
;  	;  	 :	O
respectively 	respectively 	 RB	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
selectivity  	selectivity  	 JJ	B-NP
index  	index  	 NN	I-NP
( 	( 	 -LRB-	O
SI 	SI 	 NNP	B-NP
)  	)  	 -RRB-	O
range  	range  	 NN	O
of  	of  	 IN	O
363-668 	363-668 	 CD	O
.  	.  	 .	O
In vitro  	In vitro  	 NNP	O
COX-1 	COX-1 	 NNP	O
/ 	/ 	 NNP	O
COX-2  	COX-2  	 NNP	B-NP
inhibition  	inhibition  	 VBD	I-NP
structure-activity  	structure-activity  	 JJ	I-NP
studies  	studies  	 NNS	I-NP
identified  	identified  	 VBN	O
compound  	compound  	 JJ	O
6a  	6a  	 NN	O
as  	as  	 IN	O
a  	a  	 DT	O
highly  	highly  	 RB	O
potent  	potent  	 JJ	O
( 	( 	 -LRB-	O
IC50 = 0.18 μM 	IC50 = 0.18 μM 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
an  	an  	 DT	O
extremely  	extremely  	 RB	O
selective  	selective  	 JJ	O
[ 	[ 	 -LRB-	O
COX-2  	COX-2  	 NNP	B-NP
( 	( 	 -LRB-	O
SI 	SI 	 NNP	B-NP
) 	) 	 -RRB-	O
 = 668 	 = 668 	 CD	O
]  	]  	 -RRB-	O
comparable  	comparable  	 JJ	O
to  	to  	 TO	O
celecoxib  	celecoxib  	 VB	O
[ 	[ 	 -LRB-	O
COX-2  	COX-2  	 NNP	B-NP
( 	( 	 -LRB-	O
SI 	SI 	 NNP	B-NP
) 	) 	 -RRB-	O
  	  	 CD	O
> 	> 	 CD	O
 384 	 384 	 CD	O
] 	] 	 -RRB-	O
,  	,  	 ,	O
COX-2  	COX-2  	 CD	B-NP
inhibitor  	inhibitor  	 NNS	I-NP
that  	that  	 WDT	O
showed  	showed  	 VBD	O
superior  	superior  	 JJ	O
anti-inflammatory  	anti-inflammatory  	 JJ	B-NP
activity  	activity  	 NN	I-NP
( 	( 	 -LRB-	O
ED50 = 54.0 mg 	ED50 = 54.0 mg 	 FW	B-NP
/ 	/ 	 FW	O
kg 	kg 	 FW	O
)  	)  	 -RRB-	O
relative  	relative  	 JJ	O
to  	to  	 TO	O
diclofenac  	diclofenac  	 VB	O
( 	( 	 -LRB-	O
ED50 = 114 mg 	ED50 = 114 mg 	 FW	B-NP
/ 	/ 	 FW	O
kg 	kg 	 FW	O
) 	) 	 -RRB-	O
. Molecular  	. Molecular  	 NNP	O
Docking  	Docking  	 NNP	B-NP
study  	study  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
synthesized  	synthesized  	 JJ	O
compound  	compound  	 NN	O
6a  	6a  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
active  	active  	 JJ	O
site  	site  	 NN	O
of  	of  	 IN	O
COX-2  	COX-2  	 NNP	B-NP
revealed  	revealed  	 VBD	O
a  	a  	 DT	O
similar  	similar  	 JJ	O
binding  	binding  	 JJ	O
mode  	mode  	 NN	O
to  	to  	 TO	O
SC-558 	SC-558 	 CD	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
selective  	selective  	 JJ	B-NP
COX-2  	COX-2  	 CD	I-NP
inhibitor 	inhibitor 	 NNS	I-NP
.  	.  	 .	O
Docking  	Docking  	 JJ	B-NP
study  	study  	 NN	I-NP
showed  	showed  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
methoxy  	methoxy  	 JJ	B-NP
moeities  	moeities  	 NN	I-NP
of  	of  	 IN	O
6a  	6a  	 NNP	O
inserted  	inserted  	 VBD	O
deep  	deep  	 RB	O
inside  	inside  	 IN	O
the  	the  	 DT	O
2°-pocket  	2°-pocket  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
COX-2  	COX-2  	 JJ	B-NP
active  	active  	 JJ	O
site 	site 	 NN	O
,  	,  	 ,	O
where  	where  	 WRB	O
the  	the  	 DT	O
O-atoms  	O-atoms  	 JJ	B-NP
of  	of  	 IN	O
such  	such  	 JJ	O
groups  	groups  	 NNS	O
underwent  	underwent  	 VBD	O
an  	an  	 DT	O
H-bonding  	H-bonding  	 JJ	B-NP
interaction  	interaction  	 NN	I-NP
with  	with  	 IN	O
His 	His 	 PRP$	B-NP
( 	( 	 -LRB-	I-NP
90 	90 	 CD	I-NP
)  	)  	 -RRB-	I-NP
( 	( 	 -LRB-	O
3.02 Å 	3.02 Å 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Arg 	Arg 	 NNP	B-NP
( 	( 	 -LRB-	I-NP
513 	513 	 LS	I-NP
)  	)  	 -RRB-	I-NP
( 	( 	 -LRB-	O
1.94 	1.94 	 CD	O
,  	,  	 ,	O
2.83 Å 	2.83 Å 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
Gln 	Gln 	 NNP	B-NP
( 	( 	 -LRB-	I-NP
192 	192 	 LS	I-NP
)  	)  	 -RRB-	I-NP
( 	( 	 -LRB-	O
3.25 Å 	3.25 Å 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
